[
  {"hta_id": "HIRA-2026-CGM-001", "agency": "HIRA (건강보험심사평가원)", "country": "KR", "decision_date": "2026-02-05", "device_or_intervention": "Dexcom G7 / CareSens Air / Libre 3 CGM 소모품", "indication": "제1형 당뇨병 성인 전체 + 제2형 인슐린 다회요법 환자", "decision": "급여 확대 (T2D 다회요법 적용)", "reimbursement_code": "F22501 외", "monthly_cost_kor": "본인부담 약 3-5만원/월", "evidence_basis": "DiaMonD-2 RCT, KDA 2025 권고 수용", "kor_market_impact": "T2D MDI 약 25만명 추가 수혜 추정", "relevance": ["CGM"]},
  {"hta_id": "HIRA-2026-AID-002", "agency": "HIRA + 복지부", "country": "KR", "decision_date": "2026-04-12", "device_or_intervention": "MiniMed 780G / Tandem t:slim X2 Control-IQ", "indication": "제1형 당뇨병 18세 이하 소아청소년", "decision": "급여 등재 (소아 T1D 한정 시작)", "reimbursement_code": "F22510 신설", "monthly_cost_kor": "본인부담 약 15-25만원/월(펌프 임대)", "evidence_basis": "ATTD 2025 consensus + 국내 다기관 코호트", "kor_market_impact": "국내 AID 시장 본격 개화, 성인 T1D 확대 압박", "relevance": ["AID"]},
  {"hta_id": "NECA-2026-DTx-003", "agency": "NECA (한국보건의료연구원)", "country": "KR", "decision_date": "2026-03-19", "device_or_intervention": "WELT-DM 당뇨 라이프스타일 DTx", "indication": "제2형 당뇨병 진단 1년 이내 환자", "decision": "신의료기술평가 조건부 통과", "reimbursement_code": "추후 결정 (선별급여 검토)", "monthly_cost_kor": "비급여 약 8-12만원/월 (시범)", "evidence_basis": "국내 RCT 1편 (n=420), HbA1c -0.6% (12wk)", "kor_market_impact": "국내 두 번째 DTx 본허가 + 보험연계 첫 사례", "relevance": ["DTx"]},
  {"hta_id": "NICE-TA-2026-915", "agency": "NICE (UK)", "country": "UK", "decision_date": "2026-02-22", "device_or_intervention": "Hybrid closed-loop systems (Medtronic 780G, Tandem, Omnipod 5)", "indication": "Adults with T1D and HbA1c >=7.5% or disabling hypoglycaemia", "decision": "Recommended (TA expansion)", "reimbursement_code": "NHS funded via local CCG", "monthly_cost_kor": "N/A (NHS coverage)", "evidence_basis": "ATTD 2025, HCLR registry, cost-utility £19,800/QALY", "kor_market_impact": "한국 HIRA 평가에 직접 referenced 예상", "relevance": ["AID"]},
  {"hta_id": "CADTH-2026-CGM-104", "agency": "CADTH (Canada)", "country": "CA", "decision_date": "2026-03-11", "device_or_intervention": "CGM (Dexcom G7, Libre 3, Libre 4)", "indication": "T2D MDI in adults", "decision": "Recommended with conditions", "reimbursement_code": "Provincial drug plans varies", "monthly_cost_kor": "N/A", "evidence_basis": "FLASH-UK, IMPACT, MOBILE trials", "kor_market_impact": "Canada-US harmonization, 한국 정책에 간접 영향", "relevance": ["CGM"]},
  {"hta_id": "G-BA-AMNOG-2026-DTx-021", "agency": "G-BA / BfArM (DE)", "country": "DE", "decision_date": "2026-02-14", "device_or_intervention": "Oviva Direkt für Diabetes Typ 2 DiGA", "indication": "T2D adults; lifestyle and self-management", "decision": "DiGA permanent listing", "reimbursement_code": "DiGA-VO §33a", "monthly_cost_kor": "N/A", "evidence_basis": "BfArM positive Versorgungseffekt evidence (n=620 RCT)", "kor_market_impact": "K-DTx 보험연계 모델 참조", "relevance": ["DTx"]},
  {"hta_id": "HAS-2026-DM-007", "agency": "HAS (France)", "country": "FR", "decision_date": "2026-03-29", "device_or_intervention": "FreeStyle Libre 4 (15-day)", "indication": "T1D and T2D insulin-treated adults", "decision": "SMR/ASMR maintained, 15-day reimbursement granted", "reimbursement_code": "LPPR code update", "monthly_cost_kor": "N/A", "evidence_basis": "REPLACE-BG, IMPACT, real-world France data", "kor_market_impact": "EU-wide pricing pressure", "relevance": ["CGM"]},
  {"hta_id": "ICER-2026-AID-12", "agency": "ICER (US)", "country": "US", "decision_date": "2026-04-08", "device_or_intervention": "AID systems (Medtronic 780G, Tandem, Omnipod 5, iLet)", "indication": "T1D adults and pediatrics", "decision": "Intermediate long-term value; price benchmark released", "reimbursement_code": "Commercial payer reference", "monthly_cost_kor": "N/A", "evidence_basis": "Cross-trial NMA, ATTD 2025", "kor_market_impact": "글로벌 AID 가격 협상 기준점", "relevance": ["AID"]},
  {"hta_id": "MSAC-2026-1721", "agency": "MSAC (Australia)", "country": "AU", "decision_date": "2026-04-25", "device_or_intervention": "AI DR screening (EyeArt, LumineticsCore)", "indication": "T2D primary care DR screening", "decision": "MBS item supported, conditional on rollout plan", "reimbursement_code": "MBS proposal 73020 (new)", "monthly_cost_kor": "N/A", "evidence_basis": "Australian implementation study (n=15,000)", "kor_market_impact": "한국 의원급 DR AI 수가 신설 참고", "relevance": ["SaMD"]},
  {"hta_id": "PBAC-2026-NDSS-09", "agency": "PBAC + NDSS (Australia)", "country": "AU", "decision_date": "2026-05-01", "device_or_intervention": "CGM NDSS subsidy expansion (Libre 3/4, G7)", "indication": "T2D not on insulin but high risk", "decision": "Subsidy expanded to high-risk T2D non-insulin", "reimbursement_code": "NDSS schedule update", "monthly_cost_kor": "N/A", "evidence_basis": "NDSS real-world data, ATTD 2025", "kor_market_impact": "T2D 비인슐린 CGM 급여 확대 트렌드 신호", "relevance": ["CGM"]},
  {"hta_id": "HIRA-2026-RETI-011", "agency": "HIRA + 복지부", "country": "KR", "decision_date": "2026-05-08", "device_or_intervention": "VUNO Med-Fundus AI v3 + 닥터누 당뇨 모듈", "indication": "당뇨병 환자 망막병증/심혈관 합병증 선별검사", "decision": "선별급여 (혁신의료기술) 적용", "reimbursement_code": "F-신설 (영상의학과/안과 의원급)", "monthly_cost_kor": "건당 약 1.5-3만원 (본인부담 80%)", "evidence_basis": "혁신의료기기 통합심사 + 국내 RWE", "kor_market_impact": "닥터앤서 3.0 컨소시엄 모델과 align", "relevance": ["SaMD"]},
  {"hta_id": "HIRA-2026-PEN-014", "agency": "HIRA", "country": "KR", "decision_date": "2026-04-30", "device_or_intervention": "스마트 인슐린 펜캡 (Bigfoot Unity 2, Selvas Pen Cap)", "indication": "MDI 인슐린 다회주사 환자", "decision": "행위 수가 신설 (교육수가 + 데이터수가)", "reimbursement_code": "F-신설 인슐린 자기관리 교육수가", "monthly_cost_kor": "월 약 2만원 (의료기관 교육수가)", "evidence_basis": "국내 시범사업 RWE n=1,200", "kor_market_impact": "MDI 환자 자기관리 보험 인프라 첫 사례", "relevance": ["PEN"]},
  {"hta_id": "NICE-DTx-2026-DM-DA09", "agency": "NICE (UK)", "country": "UK", "decision_date": "2026-04-17", "device_or_intervention": "Sidekick Prediabetes / Oviva DTx (Tier C ESF)", "indication": "Prediabetes adults BMI >=25", "decision": "Recommended for NHS Type 2 Diabetes Prevention Programme", "reimbursement_code": "NHS DPP framework", "monthly_cost_kor": "N/A", "evidence_basis": "ESF v3 Tier C evidence, RCT pooled", "kor_market_impact": "전당뇨 단계 DTx 정책 모델", "relevance": ["DTx"]}
]